EnnoDC’s Phase I ANRS VRI06 trial demonstrated that its Antibody Mediated Vaccine (AMV) technology induces a safe, durable, and robust immune response against HIV in human volunteers. The trial’s positive data, presented at CROI 2025, showcases the platform’s potential in treating infectious diseases and, notably, its expanding application in oncology. The study’s findings confirm the long-term effectiveness of the AMV approach, showing sustained immune responses even 80 weeks after initial treatment, further strengthened by a single booster shot.
This successful clinical proof-of-concept for AMVs holds significant implications for the future of HIV treatment and prevention. The durability of the immune response achieved with a minimal booster regimen suggests the potential for a simplified, and therefore more accessible, approach to HIV management. More broadly, the trial’s success validates the AMV platform, accelerating its application in other areas like oncology, offering a promising new avenue for developing effective cancer therapies.
Technically, the trial highlighted the AMV’s ability to engage, prime, and activate dendritic cells in vivo, resulting in a controlled and sustained immune response. This targeted approach minimizes off-target effects and maximizes therapeutic impact. Strategically, the positive results bolster EnnoDC’s advancement of its oncology pipeline, including AMV.HPVE6E7 for HPV-positive oropharyngeal cancer and AMV.PCA for prostate cancer, both leveraging the now clinically validated AMV platform.
The positive CROI 2025 data marks a pivotal moment for EnnoDC. It not only provides crucial validation for the AMV platform’s potential in infectious diseases but also reinforces the company’s strategic focus on developing innovative cancer immunotherapies. The demonstrated long-lasting immunity, combined with a favorable safety profile, positions EnnoDC to potentially revolutionize treatment approaches for both infectious diseases and cancer, paving the way for a new era of targeted immunotherapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
